Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday, January 8th.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
Several other research firms have also recently commented on ATNM. Maxim Group restated a “buy” rating and issued a $3.00 target price on shares of Actinium Pharmaceuticals in a research note on Wednesday, October 25th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. B. Riley set a $3.00 target price on Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 12th. Finally, Roth Capital restated a “buy” rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $3.75.
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.70 on Monday. Actinium Pharmaceuticals has a 1-year low of $0.54 and a 1-year high of $1.72. The firm has a market capitalization of $60.07, a PE ratio of -1.49 and a beta of 41.30.
ILLEGAL ACTIVITY NOTICE: “Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Cut to “Hold” at Zacks Investment Research” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/01/actinium-pharmaceuticals-atnm-downgraded-to-hold-at-zacks-investment-research.html.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Get a free copy of the Zacks research report on Actinium Pharmaceuticals (ATNM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.